Researchers at Zhongshan Ophthalmic Center have developed a revolutionary blood-based screening tool that identifies early diabetic retinal neurodegeneration with remarkable precision. The study, published in PLOS Medicine and involving 1,492 type 2 diabetes patients tracked over six years, identified 71 specific blood proteins capable of predicting nerve damage years before symptoms become apparent. Using advanced optical coherence tomography imaging and machine learning algorithms, the proteomics-based DRN model achieved 90.8% accuracy when combined with clinical data—substantially outperforming conventional diagnostic approaches. This breakthrough represents a paradigm shift in diabetes management, shifting focus from reactive treatment of established complications to proactive early intervention. Given that diabetes affects 422 million people worldwide and remains a leading cause of preventable blindness, this advance could have profound implications for preserving vision in vulnerable populations.
Was this article helpful?
